Conversely, another nationwide, unselected, population-based study of 600 SARS-CoV-2 patients among over 268,000 IBD patients showed that among SARS-CoV-2-infected IBD patients, neither monotherapy nor combined therapy with a TNF antagonist was associated with an increased risk of hospitalization compared to those without treatment [90]. The gene discussed is TNF; the disease is inflammatory bowel disease.